- Home
- CRVO vs ACOG Comparison
CRVO vs ACOG Comparison
Compare CRVO & ACOG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRVO
- ACOG
- Stock Information
- Founded
- CRVO 2001
- ACOG 2000
- Country
- CRVO United States
- ACOG Canada
- Employees
- CRVO N/A
- ACOG N/A
- Industry
- CRVO Biotechnology: Pharmaceutical Preparations
- ACOG
- Sector
- CRVO Health Care
- ACOG
- Exchange
- CRVO Nasdaq
- ACOG Nasdaq
- Market Cap
- CRVO 95.4M
- ACOG 91.6M
- IPO Year
- CRVO N/A
- ACOG N/A
- Fundamental
- Price
- CRVO $8.91
- ACOG $5.60
- Analyst Decision
- CRVO Strong Buy
- ACOG Strong Buy
- Analyst Count
- CRVO 8
- ACOG 1
- Target Price
- CRVO $25.43
- ACOG $20.00
- AVG Volume (30 Days)
- CRVO 13.3M
- ACOG 34.9K
- Earning Date
- CRVO 03-17-2025
- ACOG 05-20-2025
- Dividend Yield
- CRVO N/A
- ACOG N/A
- EPS Growth
- CRVO N/A
- ACOG N/A
- EPS
- CRVO N/A
- ACOG N/A
- Revenue
- CRVO $9,737,974.00
- ACOG N/A
- Revenue This Year
- CRVO N/A
- ACOG N/A
- Revenue Next Year
- CRVO N/A
- ACOG N/A
- P/E Ratio
- CRVO N/A
- ACOG N/A
- Revenue Growth
- CRVO 36.29
- ACOG N/A
- 52 Week Low
- CRVO $1.80
- ACOG $4.66
- 52 Week High
- CRVO $25.92
- ACOG $7.00
- Technical
- Relative Strength Index (RSI)
- CRVO 63.30
- ACOG N/A
- Support Level
- CRVO $8.53
- ACOG N/A
- Resistance Level
- CRVO $16.94
- ACOG N/A
- Average True Range (ATR)
- CRVO 2.01
- ACOG 0.00
- MACD
- CRVO 0.66
- ACOG 0.00
- Stochastic Oscillator
- CRVO 50.33
- ACOG 0.00
About CRVO CervoMed Inc.
CervoMed Inc is a clinical stage biotechnology company. It is focused on developing treatments for age-related neurologic disorders. The company's product candidate, Neflamapimod has the potential to treat and improve synaptic dysfunction, the reversible aspect of the underlying disease processes in DLB and certain other neurological disorders.
About ACOG Alpha Cognition Inc. Common Stock
Alpha Cognition Inc is a commercial-stage, biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer's disease and Cognitive Impairment with mild Traumatic Brain Injury (mTBI), for which there are currently no approved treatment options.